Mutual of America Capital Management LLC Cuts Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Mutual of America Capital Management LLC trimmed its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 1.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 221,552 shares of the biotechnology company’s stock after selling 3,771 shares during the period. Mutual of America Capital Management LLC owned about 0.11% of BioCryst Pharmaceuticals worth $1,327,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its stake in shares of BioCryst Pharmaceuticals by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 2,388 shares in the last quarter. Teacher Retirement System of Texas lifted its stake in BioCryst Pharmaceuticals by 4.9% in the third quarter. Teacher Retirement System of Texas now owns 53,640 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 2,519 shares during the last quarter. Fifth Third Bancorp lifted its stake in BioCryst Pharmaceuticals by 17,500.0% in the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 3,500 shares during the last quarter. Teza Capital Management LLC boosted its position in BioCryst Pharmaceuticals by 12.8% during the third quarter. Teza Capital Management LLC now owns 36,904 shares of the biotechnology company’s stock valued at $261,000 after buying an additional 4,180 shares during the period. Finally, Great Valley Advisor Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 34.7% in the third quarter. Great Valley Advisor Group Inc. now owns 16,300 shares of the biotechnology company’s stock worth $115,000 after buying an additional 4,200 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $4.41 on Tuesday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.27 and a 1 year high of $9.06. The stock’s 50-day moving average is $5.18 and its 200 day moving average is $5.58. The company has a market cap of $909.12 million, a PE ratio of -3.74 and a beta of 1.90.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The company had revenue of $93.40 million during the quarter, compared to the consensus estimate of $89.19 million. Analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “buy” rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.83.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.